Antiadenovirus activity of new fluorine-containing polypeptides - - PowerPoint PPT Presentation

antiadenovirus activity of new fluorine containing
SMART_READER_LITE
LIVE PREVIEW

Antiadenovirus activity of new fluorine-containing polypeptides - - PowerPoint PPT Presentation

Antiadenovirus activity of new fluorine-containing polypeptides mimetics Yulia Pankivska * , Liubov Biliavska, Olga Povnitsa, Svitlana Zagorodnya Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotnogo str.,


slide-1
SLIDE 1

Antiadenovirus activity of new fluorine-containing polypeptides mimetics

Yulia Pankivska *, Liubov Biliavska, Olga Povnitsa, Svitlana Zagorodnya Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotnogo str., 154, Kyiv, 03143, Ukraine

* Corresponding author: pankivska.yulia@gmail.com

slide-2
SLIDE 2

Abstract: More than 60 serotypes cause a variety of courses and severe clinical signs of infectious disease. However, there is no specific drug for the treatment of adenoviral diseases. The studying of fluorinated nucleoside sugars chemistry became the basis for the development of promising chemotherapeutic agents with antitumor and antiviral effects. Based on the purine and pyrimidine nucleotide analogs and fluorinated heterocycle molecules a number of new generation drugs with anticancer effect was developed. The reference strain of human adenovirus serotype 5 and monolayer cell line MDBK were used in the experiment. We studied new fluorine-containing compounds 10S-25(1-S-thio-(1- methylsulfonyl-2-difluoromethyl-vinyl)-2,3,4,6,-tetra-O-acetyl-β-D-glucopyranose), 10S-26 ((S)- 2-(ethoxydifluoromethyl)-pyrrolidine hydrochloride), 10S-27 (1-(β-D-glucopyranosyl)- 4- (hexafluoropropyl)-5-tosyl-1H-1,2,3-triazole), 10S-28 (Dimethyl N,N'-(2,2- difluoropropanedithioyl)bis(L-alaninate)), synthesized in Institute of Organic Chemistry of the NAS of Ukraine. Antiviral activity and the effect on adenovirus synthesized de novo were investigated. Cytotoxicity of experimental compounds was within 16 - 637 μg/ml. Antiviral activity was maximal for compound 10S-27 in the concentration of 16 μg/ml (36%). Other experimental compounds had less antiviral activity in all concentrations. However, they had a significant influence on the synthesis of viral offspring. The percentage of virus inhibition titer was in the range of 65-92%. Therefore, the experimental compounds affected the formation of the infectious viral offspring.

Keywords: adenovirus, fluorine-containing compounds, antiviral activity.

slide-3
SLIDE 3

Introduction

  • Human

adenoviruses cause various acute diseases including gastrointestinal and respiratory disorders.

  • However, there are no clinically approved specific anti-adenoviral drugs.
  • Based on the purine and pyrimidine nucleotide analogues and fluorinated

heterocycle molecules a number of new generation drugs with antiviral and anticancer effect were developed.

  • Therefore, the search of drugs and regimens that would be effective, safe

for prolonged use, and available at a cost for a wide range of patients is extremely important.

slide-4
SLIDE 4

Test compounds

10S-26 10S-25 10S-27 10S-28 Novel fluorine-containing compounds were studied:

  • 10S-25(1-S-thio-(1-methylsulfonyl-2-

difluoromethyl-vinyl)-2,3,4,6,-tetra-O-acetyl-β- D-glucopyranose),

  • 10S-26

((S)-2-(ethoxydifluoromethyl)- pyrrolidine hydrochloride),

  • 10S-27

(1-(β-D-glucopyranosyl)-4- (hexafluoropropyl)-5-tosyl-1H-1,2,3-triazole),

  • 10S-28

(Dimethyl N,N'-(2,2- difluoropropanedithioyl)bis(L-alaninate)), synthesized in Institute of Organic Chemistry

  • f the NAS of Ukraine.
slide-5
SLIDE 5

Cytotoxicity of test compounds

Cytotoxicity of the compounds was determined by MTT-test according to the standard protocol. Inoculated cell culture MDBK (bovine kidney) were used for this procedure. Cytotoxicity of experimental compounds was within the range of 16 - 637 μg/ml. CC50 indexes

100 200 300 400 500 600 700 10S25 10S26 10S27 10S28 16 637 250 541 Concentration, μg/ml

slide-6
SLIDE 6

Antiviral activity of tested compounds (was determined by MTT-test)

5 10 15 20 25 30 35 40 8 4 2 1 % of virus inhibition Concentration, μg/ml 5 10 15 20 25 30 125 62 31 16 % of virus inhibition Concentration, μg/ml 5 10 15 20 25 30 35 40 125 62 31 16 % of virus inhibition Concentration, μg/ml 25 26 27 28 29 30 31 32 33 125 62 31 16 % of virus inhibition Concentration, μg/ml

10S-26

10S-27 10S-25 10S-28

slide-7
SLIDE 7

Influence of the compounds on virus synthesized de novo (was determined by MTT-test)

62 64 66 68 70 72 74 76 4 2 1 % of redaction of virus titer Concentration of the compound, μg/ml

10S-25

50 55 60 65 70 75 80 85 90 95 125 62 31 % of reduction of virus titer Concentration of the compound, μg/ml

10S-26

66 67 68 69 70 71 72 73 62 31 16 % of reduction of virus teter Concentration of the compound, μg/ml

10S-27

10 20 30 40 50 60 70 80 125 62 31 % of reduction of virus titer Concentration of the compound, μg/ml

10S-28

slide-8
SLIDE 8
  • The test compounds showed low antiviral activity.
  • However, the effect of the compounds on the titer of the virus synthesized de

novo indicates that the compounds affect the formation of infectious virus progeny.

  • As a result, it can be assumed that fluoride-containing mimetics affect the viral
  • DNA. Although virus offspring are formed, virus particles are not complete, and

they are not able to cause an infection process.

Discussion

slide-9
SLIDE 9

Conclusions

  • The cytotoxicity of fluorine-containing compounds 10S-25, 10S-26, 10S-27,

10S28 was studied. CC50 indexes were within the range of 16 - 637 μg/ml.

  • Antiviral activity against adenovirus serotype 5 was also investigated. Percentage
  • f inhibition of the virus ranged from 3 to 36 %.
  • Fluorinated mimetic polypeptides showed a significant inhibitory effect on the

virus titer synthesized de novo. Percentage of inhibition was in the range of 60- 92%.